CTLT:NYE-Catalent Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 63.48

Change

0.00 (0.00)%

Market Cap

USD 11.52B

Volume

0.01B

Analyst Target

USD 102.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.42 (+0.26%)

USD 74.37B
HLN Haleon plc

+0.02 (+0.21%)

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

+0.18 (+1.16%)

USD 13.11B
ELAN Elanco Animal Health

+0.02 (+0.17%)

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.06 (+0.77%)

USD 3.59B
BHC Bausch Health Companies Inc

+0.05 (+0.67%)

USD 2.75B
CPHI China Pharma Holdings Inc

+0.01 (+5.00%)

USD 3.69M
YCBD cbdMD Inc

+0.01 (+2.28%)

USD 1.96M
EBS Emergent Biosolutions Inc

+0.15 (+1.84%)

N/A

ETFs Containing CTLT

XSPD:LSE Xtrackers - S&P 500 Inver.. 4.09 % 0.00 %

-0.05 (0.00%)

USD 0.10B
XSPS:LSE Xtrackers S&P 500 Inverse.. 4.09 % 0.00 %

-5.35 (0.00%)

USD 0.10B
EVNT AltShares Event-Driven ET.. 3.94 % 0.00 %

+0.02 (+0.00%)

USD 4.93M
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 3.44B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.11 (+0.00%)

N/A
JKK 0.00 % 0.30 %

N/A

N/A
MNA IQ Merger Arbitrage ETF 0.00 % 0.76 %

+0.07 (+0.00%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.04 (0.00%)

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
USLB 0.00 % 0.35 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

+0.25 (+0.00%)

USD 5.03B
TWOK 0.00 % 0.10 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

N/A

N/A
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
ARB AltShares Trust - AltShar.. 0.00 % 0.00 %

+0.08 (+0.00%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.29% 87% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.29% 87% B+ 90% A-
Trailing 12 Months  
Capital Gain 40.29% 87% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.29% 87% B+ 90% A-
Trailing 5 Years  
Capital Gain 12.91% 64% D 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.91% 57% F 41% F
Average Annual (5 Year Horizon)  
Capital Gain 5.61% 47% F 53% F
Dividend Return 5.61% 40% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.59% 40% F 20% F
Risk Adjusted Return 11.54% 47% F 28% F
Market Capitalization 11.52B 60% D- 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector